Pluronic® block copolymers in drug delivery:: From micellar nanocontainers to biological response modifiers

被引：363
作者：
Kabanov, AV [1 ]
Alakhov, VY
机构：
[1] Nebraska Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE 68198 USA
[2] Supratek Pharma Inc, Laval, PQ H7V 1B7, Canada
来源：
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS | 2002年 / 19卷 / 01期
关键词：
block copolymers; blood brain barrier; gene therapy; cancer chemotherapy; drug delivery;
D O I：
10.1615/CritRevTherDrugCarrierSyst.v19.i1.10
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Pluronic(R) block copolymers are recognized pharmaceutical excipients listed in the US and British Pharmacopoeia. The incorporation of drugs into Pluronic micelles results in increased solubility and stability of drugs. Consequently, the micelles are used for delivery of drugs in the body. Pluronic unimers sensitize multidrug-resistant cells by inhibiting drug efflux transporters. This allows for the development of formulations for the treatment of multidrug-resistant and metastatic tumors. Furthermore, these formulations can be used to enhance brain and oral bioavailability of various drugs. Finally, Pluronic formulations were shown to enhance transgene expression in the body. This opens new possibilities for the use of Pluronic in gene therapies.
引用
收藏
页码：1 / 72
页数：72
相关论文
共 337 条
[1]   RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: A pilot study [J].
AdamsGraves, P ;
Kedar, A ;
Koshy, M ;
Steinberg, M ;
Veith, R ;
Ward, D ;
Crawford, R ;
Edwards, S ;
Bustrack, J ;
Emanuele, M .
BLOOD, 1997, 90 (05) :2041-2046
[2]  
ADKISON KDK, 1994, J PHARMACOL EXP THER, V268, P797
[3]   An amorphous hydrogel enhances epithelialisation of wounds [J].
Ågren, MS .
ACTA DERMATO-VENEREOLOGICA, 1998, 78 (02) :119-122
[4]   Block copolymeric biotransport carriers as versatile vehicles for drug delivery [J].
Alakhov, V ;
Klinski, E ;
Lemieux, P ;
Pietrzynski, G ;
Kabanov, A .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (04) :583-602
[5]   Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials [J].
Alakhov, V ;
Klinski, E ;
Li, SM ;
Pietrzynski, G ;
Venne, A ;
Batrakova, E ;
Bronitch, T ;
Kabanov, A .
COLLOIDS AND SURFACES B-BIOINTERFACES, 1999, 16 (1-4) :113-134
[6]  
Alakhov V Y, 1998, Expert Opin Investig Drugs, V7, P1453, DOI 10.1517/13543784.7.9.1453
[7]   Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer [J].
Alakhov, VY ;
Moskaleva, EY ;
Batrakova, EV ;
Kabanov, AV .
BIOCONJUGATE CHEMISTRY, 1996, 7 (02) :209-216
[8]  
ALAKHOV VY, Patent No. 5817321
[9]   SURFACE-ACTIVITY OF POLY(ETHYLENE OXIDE)-BLOCK-POLY(PROPYLENE OXIDE)-BLOCK-POLY(ETHYLENE OXIDE) COPOLYMERS [J].
ALEXANDRIDIS, P ;
ATHANASSIOU, V ;
FUKUDA, S ;
HATTON, TA .
LANGMUIR, 1994, 10 (08) :2604-2612
[10]  
Alexandridis P, 2000, AMPHIPHILIC BLOCK COPOLYMERS: SELF-ASSEMBLY AND APPLICATIONS, P169, DOI 10.1016/B978-044482441-7/50009-8
12345678910